- Home
- HSPO vs CYCC Comparison
HSPO vs CYCC Comparison
Compare HSPO & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- CYCC
- Stock Information
- Founded
- HSPO 2014
- CYCC 1992
- Country
- HSPO United States
- CYCC Malaysia
- Employees
- HSPO N/A
- CYCC N/A
- Industry
- HSPO Blank Checks
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- CYCC Health Care
- Exchange
- HSPO Nasdaq
- CYCC Nasdaq
- Market Cap
- HSPO 49.4M
- CYCC 47.6M
- IPO Year
- HSPO 2022
- CYCC N/A
- Fundamental
- Price
- HSPO $11.79
- CYCC $0.25
- Analyst Decision
- HSPO
- CYCC Strong Buy
- Analyst Count
- HSPO 0
- CYCC 1
- Target Price
- HSPO N/A
- CYCC $11.00
- AVG Volume (30 Days)
- HSPO 242.0
- CYCC 7.3M
- Earning Date
- HSPO 01-01-0001
- CYCC 05-20-2025
- Dividend Yield
- HSPO N/A
- CYCC 59.13%
- EPS Growth
- HSPO N/A
- CYCC N/A
- EPS
- HSPO 0.27
- CYCC N/A
- Revenue
- HSPO N/A
- CYCC $43,000.00
- Revenue This Year
- HSPO N/A
- CYCC $137.21
- Revenue Next Year
- HSPO N/A
- CYCC N/A
- P/E Ratio
- HSPO $44.35
- CYCC N/A
- Revenue Growth
- HSPO N/A
- CYCC N/A
- 52 Week Low
- HSPO $10.87
- CYCC $0.17
- 52 Week High
- HSPO $12.41
- CYCC $3.08
- Technical
- Relative Strength Index (RSI)
- HSPO 46.31
- CYCC 47.06
- Support Level
- HSPO $11.78
- CYCC $0.28
- Resistance Level
- HSPO $11.90
- CYCC $0.37
- Average True Range (ATR)
- HSPO 0.02
- CYCC 0.07
- MACD
- HSPO -0.02
- CYCC 0.01
- Stochastic Oscillator
- HSPO 5.00
- CYCC 20.67
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.